To Protect the Public, FDA Should Go Beyond Industry's Petition on BPA

Aimee Simpson

April 18, 2012

CPR Member Scholar Noah Sachs and I submitted comments yesterday to FDA regarding the American Chemistry Council’s (ACC) petition to the agency on BPA. In September, the ACC petitioned FDA to remove approval for the use of BPA in “infant feeding bottles and certain spill-proof cups” (Rena Steinzor and I explained at the time the story behind the seemingly counter-intuitive move).

In our comments this week, we advocate for FDA to utilize its full rulemaking authority and take broader regulatory action to protect the public against BPA.  Specifically, we propose:

  • Issuing new regulations encompassing the ACC’s Petition and Rep. Edward Markey’s March 16, 2012 Petitions concerning abandoned uses;
  • Banning a much broader range of BPA uses without reference to age limits or target consumers; and
  • Mandating labeling of BPA in all food contact materials.

As we explain in the comments, convincing scientific evidence supports these broader measures because of the demonstrated low-dose effects of BPA and other endocrine disrupting chemicals.  These low-dose effects are not properly accounted for in current risk assessments of BPA and it is the role of FDA to act on behalf of all consumers' safety.

Read More by Aimee Simpson
CPR HOMEPAGE
More on CPR's Work & Scholars.
June 30, 2022

Supreme Court Swings at Phantoms in West Virginia v. EPA

June 29, 2022

The Revelator Op-Ed: Regulators Have a Big Chance to Advance Energy Equity

June 28, 2022

New Yorkers' Environmental Rights Are Under Attack

June 27, 2022

Two FERC Cases and Why They Matter

June 23, 2022

Member Scholar Buzbee Leads Congressional Amicus in Crucial Supreme Court Clean Water Act Case

June 23, 2022

Justices Overturn Washington Workers' Compensation Law on a Strict Reading of Intergovernmental Immunity

June 22, 2022

Addressing Overburdened, Underserved Communities' Priorities Is Vital to Success of California Climate Plan